Noxopharm Ltd's (ASX:NOX) Dr Graham Kelly speaks to Proactive soon after announcing that a CEP-2 study will begin shortly for the US Food and Drug Administration (FDA) approved Investigational New Drug (IND) application for Veyonda® in first-line sarcoma treatment. The study, which is part of the company’s Chemotherapy Enhancement Program (CEP), is set to proceed with a contract research organisation appointed. IND was granted by the FDA last year on evidence that Veyonda may increase generally poor response rates of sarcoma cancers to chemotherapy.
Noxopharm's Dr Graham Kelly outlines its four pillars oncology strategy
